William Blair Analysts Reduce Earnings Estimates for Agenus

Agenus Inc. (NASDAQ:AGEN) – Investment analysts at William Blair dropped their Q4 2024 EPS estimates for Agenus in a research note issued to investors on Tuesday, November 12th. William Blair analyst M. Phipps now expects that the biotechnology company will post earnings of ($2.85) per share for the quarter, down from their previous estimate of ($2.81). The consensus estimate for Agenus’ current full-year earnings is ($10.26) per share. William Blair also issued estimates for Agenus’ Q1 2025 earnings at ($2.90) EPS, Q2 2025 earnings at ($3.07) EPS, Q3 2025 earnings at ($3.22) EPS, Q4 2025 earnings at ($3.31) EPS, FY2025 earnings at ($12.51) EPS, FY2026 earnings at ($13.03) EPS and FY2027 earnings at ($12.97) EPS.

Other analysts also recently issued reports about the stock. StockNews.com downgraded shares of Agenus from a “hold” rating to a “sell” rating in a report on Monday, August 12th. HC Wainwright cut their price target on Agenus from $8.00 to $7.00 and set a “neutral” rating for the company in a research note on Tuesday, November 12th. Finally, B. Riley decreased their target price on shares of Agenus from $42.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $10.00.

Agenus Price Performance

AGEN opened at $2.72 on Friday. The stock’s 50 day moving average price is $4.70 and its 200 day moving average price is $8.67. The stock has a market cap of $63.81 million, a P/E ratio of -0.24 and a beta of 1.39. Agenus has a 12 month low of $2.58 and a 12 month high of $19.69.

Institutional Trading of Agenus

Several institutional investors have recently modified their holdings of AGEN. Point72 DIFC Ltd bought a new position in Agenus in the 2nd quarter valued at $51,000. EP Wealth Advisors LLC bought a new stake in Agenus in the third quarter valued at about $55,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Agenus during the second quarter valued at approximately $106,000. BNP Paribas Financial Markets grew its holdings in shares of Agenus by 81.3% in the 1st quarter. BNP Paribas Financial Markets now owns 188,414 shares of the biotechnology company’s stock valued at $109,000 after buying an additional 84,477 shares during the period. Finally, HighTower Advisors LLC grew its position in shares of Agenus by 46.1% in the 3rd quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 7,530 shares during the period. Institutional investors and hedge funds own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.